MELIOIDOSIS IN NORTHERN AUSTRALIA AN …
Transcript of MELIOIDOSIS IN NORTHERN AUSTRALIA AN …
8/04/2015
1
INFECTIOUS DISEASES &
IMMUNOPATHOGENESIS
RESEARCH GROUP
Dr Robert Norton
Director of Microbiology and Pathology
Townsville, Queensland
Australia
MELIOIDOSIS IN
NORTHERN AUSTRALIA
– AN ENVIRONMENTAL
DISEASE
No (financial or other) conflicts to disclose
8/04/2015
2
So why do you need to know about
Melioidosis ?
Increased travel to and from endemic regions
Was once this……
8/04/2015
3
Is now this……
Climate change
8/04/2015
4
From this
Because of this
8/04/2015
5
To this
And then there’s this
8/04/2015
6
We may use it as a biological weapon
History of Melioidosis
“There is prevalent in Rangoon a
particular septicaemic or pyaemic
disease caused by an infestation with a
bacillus whose characteristics are so
distinct from other known pathogenic
bacteria that it can be readily isolated
and certainly identified”
8/04/2015
7
Worldwide distribution of Melioidosis
• Taxonomical changes:
Bacillus mallei, Bacillus whitmori,
Pfeifferella pseudomallei;
Malleomyces pseudomallei;
Pseudomonas pseudomallei;
Burkholderia pseudomallei
Burkholderia pseudomallei • Gram negative, oxidase positive, aerobic non-fermenter
• A widely distributed environmental organism
• Isolated more commonly from soil in NE Thailand & Australia
• A Category B bioterrorism agent (CDC)
• Clear relationship between the water content of soil and organism
numbers.
• Possible interaction between B. pseudomallei and specific plant roots
,amoebae and soil type.
8/04/2015
8
Route of Acquisition & Risk Factors
Definitive evidence Inoculation
Aspiration of fresh water
Circumstantial evidence Inhalation
Ingestion of contaminated water
Person to person
Zoonotic spread
15-25 cases per year in our region
Age (30 - 65 years)
Sex - M>F
Indigenous ethnicity
Outdoor occupation
Diabetes mellitus, renal disease
Immune suppression
Alcohol intake
Malczewski A et al. Trans R Soc Med 2005;99:856-860
Year 2000 Annual rainfall 2400mm
23 cases; 7 fatalities
0
1200
Month
Rain
fall
(m
m)
0
15
Nu
mb
er
of
Cases
Rainfall No. of Cases
Incidence Correlates With Rainfall
Malczewski A et al. Trans R Soc Med 2005;99:856-860
8/04/2015
9
DIAGNOSIS
Clinical suspicion
Culture of blood, pus, sputum
Serology is of limited value as it is
often negative early in the
disease
Sub-acute or Chronic Presentation Visceral abscesses
Pancreas, Liver, Spleen, Prostate
Osteomyelitis or pyogenic arthritis
Soft tissue abscesses
Muscle
Sub-cutaneous
Skin-ulcers
Pneumonia
Septicaemia
Meningo-encephalitis
Acute Presentation
Antibody positive
Reactivation if immunocompromised
Latent Infection
Spectrum of Diverse Clinical Presentations
Townsville data (1996 – 2013)
Organ No.patients (n %) Mortality (n %)
Lung 103 (45%) 25 (24%)
Genitourinary 23 (10%) 1 (4%)
Skin and soft tissue 19 (8%) 0
Bone and joint 14 (6%) 0
Neurological 13 (5.6%) 5 (38%)
No source 19 (8%) 3 (16%)
Other/Mixed source
38 (16.6%) 9 (24%)
Total 229 43 (18.7%)
8/04/2015
10
Outcomes
• If untreated or inadequately treated: >70% mortality
• With optimal treatment including availability of ICU – 15-20%
• Mortality related to co-morbidities and organ involvement. (CNS infection –
40%)
Case 1 – Melioidosis and Pneumonia
AK
35 year old solicitor.
No risk factors
House was affected by flooding in recent rains.
Three week history of cough, breathlessness, fever and weight loss.
Sputum grew B.pseudomallei.
8/04/2015
11
Case 1 - Progress
• Commenced on Ceftazidime and cotrimoxazole.
Serology
Date from admission IHA EIA IgG / IgM
Day 0 1:40 Neg/Neg
Day 22 1:640 Neg/Pos
Day 52 1:2560 Pos/Pos
8/04/2015
12
Case 1 - Progress
• Completed 4 weeks Ceftazidime
• Kept on maintenance cotrimoxazole for a further 3 months.
• Full recovery.
Case 2 – Neurological disease
• A 12 year old non-indigenous female
– Admitted to a regional hospital. Fever, headache, cough, vomiting,
photophobia, Ophthalmoplegia (bilateral).
– LP, CSF (protein 520, WCC 190, Gram stain - No organisms seen).
– Dropped GCS (<8/15) with respiratory arrest.
– Intubated uneventfully and transferred to ICU.
8/04/2015
13
Case 2
• Social History
• Used to live in PNG (malaria 4 yrs ago).
• Was helping her father with irrigation pipes in the rain before
onset of symptoms.
• Progress
• CT head Normal
• Started on meropenem, ceftriaxone, ciprofloxacin ,
cotrimoxazole and acyclovir.
Chest X ray on admission to ICU
8/04/2015
14
T2 weighted MRI
8/04/2015
15
Diagnosis: CNS and pulmonary melioidosis.
Protracted clinical course including severe neurological deficit and
prolonged ICU stay.
Discharged home following rehabilitation and on maintenance
cotrimoxazole.
Case 2
• Clinical suspicion
• Early microbiological diagnosis
• Imaging to determine the extent of disease
• Drainage of abscesses as necessary
• Combination therapy with Ceftazidime or Meropenem with
Cotrimoxazole or Doxycycline
• Prolonged suppressive therapy with Cotrimoxazole or
Doxycycline
Management
8/04/2015
16
Oxidase pos, Gram negative bacillus
Gentamicin and colistin resistant
Amoxycillin/clavulanate sensitive
PCR on blood is insensitive
Laboratory Diagnosis (Presumptive)
The place of serology
• Indirect haemaglutination assay
– Of limited value in diagnosis
– 50% of culture positive specimens are IHA negative at the time of presentation.
– A reasonable marker of active disease if strongly positive.
• Enzymeimmunoassay (EIA) IgG
– More sensitive than the IHA
– Of limited use in an endemic area where background seropositivity can be 7%
– Does not distinguish between previous disease or exposure and current disease
8/04/2015
17
Host factors
Genotype
Genetic predisposition – ?TLR, TNF receptors
Antibody to B. pseudomallei
Appears post infection and does not seem to prevent relapse
Cell Mediated Immunity to B. pseudomallei
Highly significant
Bacterial factors
Virulence Determinants
Lipopolysaccharide (endotoxin)
Exotoxins - cytolethal toxin, haemolysin
Iron - fur (ferric uptake regulator)
Type III secretion system proteins
Factors Influencing Disease Outcome
Melioidosis and Cystic fibrosis
• Uncommon
• Related to residence in or travel to an endemic area
• Human to human transmission is speculative at this point
• Tends to colonise rather than cause severe sepsis.
• Nevertheless does need to be treated.
8/04/2015
18
B.pseudomallei and the environment
• A clear relationship between disease and intensity of rainfall . Particularly with
cyclonic conditions.
• Contact in certain areas within the endemic region are more likely to result in
infection than others,
• Contact with surface water seems more important than contact with soil.
• The presence of risk factors is an important part of risk assessment.
– Diabetes
– Alcohol consumption
– Indigenous ethnicity
B.pseudomallei and the environment
Isolates are genetically diverse and only occasionally is there
a clear proven link between an environmental isolate and a clinical one.
M.Corkeron et al, Epidemiol Infect 2010, 22:1-7.
8/04/2015
19
Current Research
• Diagnostics
– Antigen detection using a lateral flow immunoassay
– Improving serological diagnosis with improved antigens
• Environmental
– Determining the ecological niche and interaction with soil types
• The role of diabetes in the pathogenesis of this disease
– Cellular and cytokine responses in diabetics vs non-diabetics
B.pseudomallei as an agent of bioterrorism
• Is currently a recognised agent of bioterrorism
– Can survive in the environment for lengthy periods
– Can be difficult to identify in laboratories unfamiliar with it
– Difficult to treat with simple antibiotics
– Will use up resources
– Has a high mortality if not treated adequately particularly among diabetics
– Can be weaponised
– No vaccine
8/04/2015
20
Conclusions
• Burkholderia pseudomallei is an important cause of community acquired
pneumonia in endemic regions of Australia.
• With increased travel, patients may and have presented to hospitals in
southern areas where the diagnosis may not be apparent,
• Laboratory diagnosis is primarily by culture.
• There is a clear relationship between the intensity of rainfall in an endemic
area and disease.
• Treatment is with meropenem or ceftazidime followed by maintenance
cotrimoxazole or doxycycline.